Sino Biopharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Sino Biopharmaceutical CEO'su Eric Tse, Jul2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı CN¥ 50.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 45.4% maaş ve 54.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 22.66% ine doğrudan sahiptir ve bu hisseler HK$ 17.07B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.3 yıl ve 10 yıldır.

Anahtar bilgiler

Eric Tse

İcra Kurulu Başkanı

CN¥50.7m

Toplam tazminat

CEO maaş yüzdesi	45.40%
CEO görev süresi	2.8yrs
CEO sahipliği	22.7%
Yönetim ortalama görev süresi	6.3yrs
Yönetim Kurulu ortalama görev süresi	10yrs

Son yönetim güncellemeleri

Recent updates

Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

May 06

Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Apr 30

Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Jan 13

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Dec 08

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12

CEO Tazminat Analizi

Eric Tse'un ücretlendirmesi Sino Biopharmaceutical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	CN¥51m	CN¥23m	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥50m	CN¥23m	CN¥2b
Jun 30 2023	n/a	n/a	CN¥1b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

Tazminat ve Piyasa: Eric 'nin toplam tazminatı ($USD 7.04M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 685.82K ).

Tazminat ve Kazançlar: Eric 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Eric Tse (28 yo)

2.8yrs

Görev süresi

CN¥50,704,000

Tazminat

Mr. S. Y. Tse, also known as Eric, serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sin...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Y. Y. Tse	Executive Chairwoman of the Board	9.9yrs	CN¥50.70m	0.034% HK$ 25.3m
S. Y. Tse	CEO & Executive Director	2.8yrs	CN¥50.70m	22.66% HK$ 17.1b
Ping Tse	Founder & Senior Executive Vice Chairman	4.8yrs	CN¥50.45m	9.27% HK$ 7.0b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	8.1yrs	CN¥44.01m	16.59% HK$ 12.5b
Zhoushan Tian	Executive Director	no data	CN¥1.86m	Veri yok
Hsin Tse	Senior VP & Executive Director	no data	CN¥5.21m	2% HK$ 1.5b
Chun Ling Li	Chief Financial Officer	2.3yrs	Veri yok	Veri yok
Song Jin	Vice President of Public Affairs	no data	Veri yok	Veri yok
Oi Nin Chan	Company Secretary	9.8yrs	Veri yok	Veri yok

6.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: 1177 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Y. Y. Tse	Executive Chairwoman of the Board	9.9yrs	CN¥50.70m	0.034% HK$ 25.3m
S. Y. Tse	CEO & Executive Director	5.6yrs	CN¥50.70m	22.66% HK$ 17.1b
Ping Tse	Founder & Senior Executive Vice Chairman	4.8yrs	CN¥50.45m	9.27% HK$ 7.0b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	8.1yrs	CN¥44.01m	16.59% HK$ 12.5b
Zhoushan Tian	Executive Director	10.1yrs	CN¥1.86m	Veri yok
Hsin Tse	Senior VP & Executive Director	no data	CN¥5.21m	2% HK$ 1.5b
Zhengfei Lu	Independent Non-Executive Director	19.5yrs	CN¥384.00k	Veri yok
Dakui Li	Independent Non-Executive Director	20.7yrs	CN¥384.00k	Veri yok
Lu Fu Zhang	Independent Non-Executive Director	10.1yrs	CN¥383.00k	Veri yok
Hong Lu	Independent Non-Executive Director	10.1yrs	CN¥349.00k	Veri yok
Kwok Tung Li	Independent Non-Executive Director	4.4yrs	CN¥383.00k	0.00040% HK$ 301.3k

10.0yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1177 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/22 20:26
Gün Sonu Hisse Fiyatı	2025/05/22 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Sino Biopharmaceutical Limited 54 Bu analistlerden 23, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ling Zhang	BNP Paribas Securities (Asia)
Justin Liu	BNP Paribas Securities (Asia)
Sharon Shi	BOCI Research Ltd.

Sino Biopharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 10, 2025

Key Executive recently sold HK$51m worth of stock

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Key Executive recently bought HK$34m worth of stock

Recent updates

Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Biopharmaceutical Limited Announces Application for Clinical Trial of "TQB3019 (BTK PROTAC)" Approved by NMPA

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Sino Biopharmaceutical Limited Announces Approval for Clinical Trial of TQB2101 (RR1 ADC)

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Culmerciclib in Combination with Fulvestrant for First-Line Treatment of H-Positive and HER2-Negative Breast Cancer

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Final dividend of HK$0.04 announced

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 10, 2025

Sino Biopharmaceutical Limited Announces Publication of Results from Phase Ib/IIa Clinical Study of "Rovadicitinib"

Sino Biopharmaceutical Limited to Report Fiscal Year 2024 Results on Mar 20, 2025

Sino Biopharmaceutical Limited Announces Approval for Marketing of the First Generic Tulobuterol Patches

Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy

Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma

Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold HK$51m worth of stock

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

First half 2024 earnings: EPS and revenues exceed analyst expectations

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

Consensus EPS estimates increase by 11%

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Investor sentiment improves as stock rises 18%

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Consensus revenue estimates fall by 13%

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%